New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin

F1000Research
Filippo CaraciFilippo Drago

Abstract

Behavioral and psychological symptoms of dementia are symptoms of disturbed perception, mood, behavior, and thought content that occurred frequently. These symptoms, which include apathy, depression, anxiety, psychosis, agitation, and aggression, can serve as predictors of and early clinical diagnostic markers for Alzheimer's disease (AD) and are common precipitants of institutional care. Agitation and psychosis are associated with accelerated disease progression and increased tau phosphorylation in patients with AD. Current guidelines recommend the use of second-generation antipsychotics for the treatment of agitation and psychosis in AD, but only after first-line non-pharmacological interventions and for no longer than 12 weeks because long-term use of these drugs is associated with an increased risk of mortality and an increased frequency of cerebrovascular events. Therefore, new antipsychotic drugs with improved efficacy and safety are needed as an alternative to current antipsychotic drugs. In this report, we discuss some of the most relevant advances in the field of agitation and psychosis in AD and focus on the recent positive clinical evidence observed with two new antipsychotics drugs: brexpiprazole and pimavanserin. B...Continue Reading

References

May 1, 1989·Journal of Gerontology·J Cohen-MansfieldA S Rosenthal
May 8, 2002·International Journal of Geriatric Psychiatry·Michal Schnaider BeeriShlomo Noy
Apr 13, 2005·Archives of Internal Medicine·Sudeep S GillPaula A Rochon
Mar 1, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Lon S SchneiderPhilip S Insel
May 23, 2006·Nature Reviews. Neuroscience·Clive Ballard, Robert Howard
Jun 1, 2006·Expert Review of Neurotherapeutics·Rita MorettiGilberto Pizzolato
Sep 29, 2011·JAMA : the Journal of the American Medical Association·Alicia Ruelaz MaherPaul G Shekelle
Feb 14, 2012·Current Treatment Options in Neurology·Anne CorbettClive Ballard
Apr 10, 2013·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Paul B RosenbergConstantine G Lyketsos
Jul 9, 2013·Ageing Research Reviews·Deirdre A RobertsonRose Anne Kenny
Nov 26, 2013·Journal of Alzheimer's Disease : JAD·Patrick S MurrayRobert A Sweet
Apr 2, 2014·Journal of Alzheimer's Disease : JAD·Yannick VermeirenPeter P De Deyn
Apr 5, 2014·The American Journal of Psychiatry·Yonas E GedaWalter A Rocca
Jun 21, 2014·The Journal of Pharmacology and Experimental Therapeutics·Kenji MaedaTetsuro Kikuchi
Oct 15, 2014·International Psychogeriatrics·Jeffrey CummingsUNKNOWN International Psychogeriatric Association
May 27, 2015·Nature Neuroscience·Erik S Musiek, David M Holtzman
Oct 21, 2015·Journal of Alzheimer's Disease : JAD·David BensamounRenaud David
Jul 1, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Krista L LanctôtEleenor H Abraham
Dec 14, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·David NuttSue Wilson
Jan 20, 2017·Therapeutic Advances in Psychopharmacology·Joshua S Frankel, Thomas L Schwartz
Mar 17, 2017·Expert Opinion on Pharmacotherapy·Anton P Porsteinsson, Inga M Antonsdottir
Apr 13, 2017·British Journal of Clinical Pharmacology·Filippo CaraciFilippo Drago
Jan 18, 2018·Journal of Psychopharmacology·Simon Jc DaviesTarek K Rajji
May 10, 2018·Lancet·Paul Webster
May 17, 2018·Expert Review of Neurotherapeutics·Byron CreeseClive Ballard
May 23, 2018·Neuropsychiatric Disease and Treatment·Jiří MasopustBlanka Klímová
Oct 10, 2018·The Journal of Prevention of Alzheimer's Disease·J CummingsS Stankovic
Dec 21, 2018·The Journal of Prevention of Alzheimer's Disease·C BallardS Stankovic
Jan 31, 2019·Neuropsychiatric Disease and Treatment·Kristen Ward, Leslie Citrome
Apr 23, 2019·Trends in Neurosciences·Frances A Edwards
Jul 3, 2019·Current Psychiatry Reports·Laurel J Bessey, Art Walaszek
Nov 12, 2019·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·George T GrossbergJeffrey L Cummings
Dec 10, 2019·Current Pharmaceutical Design·Giuseppe CarusoSara Merlo
Feb 20, 2020·Neuroscience and Biobehavioral Reviews·Filip KoselTamara B Franklin

❮ Previous
Next ❯

Citations

Feb 23, 2021·Expert Opinion on Pharmacotherapy·Rita KhouryGeorge T Grossberg

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
sedation

Clinical Trials Mentioned

NCT01862640
NCT03724942
NCT03594123
NCT03545584
NCT00477672
NCT00658567
NCT01174004
NCT03325556
NCT01922258
NCT03620981

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here